Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension
NCT00424541
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypertension
Interventions
DRUG:
SPP100 (aliskiren)
Sponsor
Novartis